Open Access Full Text Article

RETRACTION

Emodin Suppresses Proliferation, Migration and Invasion in Ovarian Cancer Cells by down Regulating ILK in vitro and in vivo [Retraction]

Lu JJ, Xu Y, Zhao Z, et al. Onco Targets Ther. 2017;10:3579-3589.

At the authors request, the Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. The authors raised concerns after discovering the duplication of cell migration and invasion images in Figures 1 and 2. Specifically,

- Figure 1E, A2780, Migration, Normal appears to have been duplicated with Figure 1E, A2780, Migration pLVX-Con.
- Figure 1E, SK-OV-3, Invasion, Normal appears to have been duplicated with Figure 2C, SK-OV-3, Invasion, pLVX-Con+, pLVX-ILK-, Emodin-.

The authors provided original data and requested to retract the article. All the authors agreed that the retraction was necessary for reasons of scientific accuracy. The Editor agreed with this decision.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

85 I

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S385443

Received: 8 August 2022 Accepted: 8 August 2022 Published: 10 August 2022

OncoTargets and Therapy 2022:15 851

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com. the work you hereby accept the Terms.Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).